{"prompt": "['Document Type:', 'Study Protocol', 'Official Title:', 'A randomized parallel-group, placebo-controlled, double-blind,', 'multi-center trial to evaluate the efficacy and safety of the oral sGC', 'stimulator vericiguat to improve physical functioning in activities of', 'daily living in patients with heart failure and preserved ejection', 'fraction (VITALITY-HFpEF)', 'NCT Number:', 'NCT03547583', 'Document Date:', '22-Feb-2018']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 1 of 81', '1.', 'Title page', 'A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate', 'the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical', 'functioning in activities of daily living in patients with heart failure and preserved ejection', 'fraction (VITALITY-HFpEF)', 'Short title: Patient-reported outcomes in vericiguat-treated patients with HFpEF', 'Acronym:', 'VITALITY-HFpEF', 'Test drug:', 'Vericiguat / BAY 1021189', 'Study purpose:', 'To assess the safety and efficacy of vericiguat in reducing physical', 'limitations in patients with heart failure and preserved ejection', 'fraction', 'Clinical study phase:', 'Phase IIb', 'Date:', '22 FEB 2018', 'Registration:', '2018-000298-65', 'Version no.:', '1.0', \"Sponsor's study no.:\", '19334', 'Sponsor:', 'Bayer AG, D-51368 Leverkusen, Germany', 'US territory: Bayer HealthCare Pharmaceuticals Inc., 100 Bayer', 'Boulevard, PO box 915, Whippany, NJ 07981-0915 United States', \"Sponsor's medical expert:\", 'PPD', 'Bayer SA', 'Rua Cancioneiro de \u00c9vora, 255 - Pr\u00e9dio E1 - 1\u00b0 andar', '04708-010 S\u00e3o Paulo - SP Brazil', 'SP Brazil', 'Phone no.', 'PPD', 'The study will be conducted in compliance with the protocol, ICH-GCP and any applicable', 'regulatory requirements.', 'Confidential', 'The information provided in this document is strictly confidential and is intended solely for', 'the guidance of the clinical investigation. Reproduction or disclosure of this', 'document - whether in part or in full - to parties not associated with the clinical', 'investigation or its use for any other purpose without the prior written consent of the', 'sponsor is not permitted.', 'Throughout this document, symbols indicating proprietary names (R, TM) may not be displayed.', 'Hence, the appearance of product names without these symbols does not imply that these names are not protected.']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 2 of 81', \"Signature of the sponsor's medically responsible person\", 'The signatory agrees to the content of the final clinical study protocol as presented.', 'Name: PPD', 'Role:', 'PPD', 'Date: Feb 22,2018', 'Signature:']\n\n###\n\n", "completion": "END"}